Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: pass (415), intervene (25), slip away (21)

Myeloma VCD (IV35) bortezomib (IV) cyclophosphamide dexamethasone 35 day

Description: Chemotherapy Protocol MULTIPLE MYELOMA VCD (IV-35) - BORTEZOMIB (IV)-CYCLOPHOSPHAMIDE-DEXAMETHASONE (35 day) Regimen
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Myeloma-VCD-IV35-bortezomib-IV-cyclophosphamide-dexamethasone-35-day.pdf

Ipilimumab-Nivolumab

Description: Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication • Ipilimumab i
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf

Ipilimumab-Nivolumab Ver1

Description: Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in combination with ipilimumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Th
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHA
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

AmB - Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Mantle Cell lymphoma (MCL) AmB – BREXUCEL – CYCLOPHOSP
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Brexucel-Cyclophosphamide-500-Fludarabine-30-Ver-1.pdf

MyelomaBortezomib IV DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (IV)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple M
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-IV-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

Ipilimumab(1mg/kg)-Nivolumab(3mg/kg)

Description: Chemotherapy Protocol RENAL CANCER IPILIMUMAB (1mg/kg)-NIVOLUMAB(3mg/kg) Regimen • Renal – Ipilimumab (1mg/kg)-Nivolumab (3mg/kg) Indication • Ipilimumab in c
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Ipilimumab1mgkg-Nivolumab3mgkg.pdf

MyelomaBortezomib SC DexamethasonePabinostatThalidomide 21day Ver1.1

Description: Chemotherapy Protocol MULTIPLE MYELOMA BORTEZOMIB (SC)-DEXAMETHASONE-PANOBINOSTAT-THALIDOMIDE Regimen (21 day) • Multiple M
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaBortezomib-SC-DexamethasonePabinostatThalidomide-21day-Ver1.1.pdf

21 to 30 of 35

Previous 1 2 3 4 Next